CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


COVID-19 diagnostic testWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1981 Questionnaire by phone call Wiki 1.00

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D012859 Sjogren's Syndrome NIH 0.71
D001327 Autoimmune Diseases NIH 0.58
D015535 Arthritis, Psoriatic NIH 0.50
D008180 Lupus Erythematosus, Systemic NIH 0.41
D001168 Arthritis NIH 0.29

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0002960 Autoimmunity HPO 0.58
HP:0002725 Systemic lupus erythematosus HPO 0.41
HP:0001369 Arthritis HPO 0.29

There is one clinical trial.

Clinical Trials


1 Dynamic Evaluation of COVID-19 Diagnostic Tests

Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been evaluated. We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.

NCT04337996 COVID-19 Diagnostic Test: COVID-19 diagnostic test

Primary Outcomes

Description: Comparison of the Gold-Standard PCR, anamnesis, thoracic CT scan versus SARS-Cov-2 antigen, anamnesis and thoracic CT scan

Measure: Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies

Time: day 1

Secondary Outcomes

Description: Number of diagnoses invalidated by the antigen + CT scan alone without the contribution of PCR.

Measure: Positive or negative Covid-19 test

Time: day 1

Description: Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19

Measure: Positive or negative character of the antibodies test

Time: day 1

Description: Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19 at the time of hospitalization

Measure: Positive or negative character of the antibodies test

Time: day 21

Description: Evolution of biological parameters as a function of time IgM IgA and IgG

Measure: Biological parameters

Time: day 1

Description: Evolution of biological parameters as a function of time IgM IgA and IgG

Measure: Biological parameters

Time: Day 21

Description: medical-economic comparison of the first-line use of the antigenic test

Measure: medical-economic comparison

Time: day 1


No related HPO nodes (Using clinical trials)